$62.87
0.33% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
GB00BYMT0J19
Symbol
LIVN

Livanova PLC Stock price

$62.87
-0.97 1.52% 1M
+17.07 37.27% 6M
+16.56 35.76% YTD
+15.81 33.60% 1Y
+9.17 17.08% 3Y
-4.66 6.90% 5Y
+2.62 4.35% 10Y
+29.12 86.28% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.21 0.33%

Key metrics

Basic
Market capitalization
$3.4b
Enterprise Value
$3.2b
Net debt
positive
Cash
$646.1m
Shares outstanding
55.0m
Valuation (TTM | estimate)
P/E
negative | 16.0
P/S
2.5 | 2.4
EV/Sales
2.4 | 2.3
EV/FCF
16.8
P/B
3.0
Financial Health
Equity Ratio
52.7%
Return on Equity
4.8%
ROCE
11.7%
ROIC
17.3%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$1.3b | $1.4b
EBITDA
$247.0m | $333.5m
EBIT
$202.5m | $289.0m
Net Income
$-217.0m | $216.3m
Free Cash Flow
$192.0m
Growth (TTM | estimate)
Revenue
8.6% | 12.3%
EBITDA
38.6% | 63.3%
EBIT
51.5% | 78.4%
Net Income
-1,014.5% | 243.4%
Free Cash Flow
77.7%
Margin (TTM | estimate)
Gross
68.5%
EBITDA
18.3% | 23.7%
EBIT
15.0%
Net
-16.1% | 15.4%
Free Cash Flow
14.2%
More
EPS
$-3.9
FCF per Share
$3.5
Short interest
4.6%
Employees
3k
Rev per Employee
$430.0k
Show more

Is Livanova PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Livanova PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Livanova PLC forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a Livanova PLC forecast:

Buy
75%
Hold
25%

Financial data from Livanova PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,349 1,349
9% 9%
100%
- Direct Costs 425 425
6% 6%
32%
924 924
10% 10%
68%
- Selling and Administrative Expenses 547 547
4% 4%
41%
- Research and Development Expense 177 177
5% 5%
13%
247 247
39% 39%
18%
- Depreciation and Amortization 44 44
0% 0%
3%
EBIT (Operating Income) EBIT 203 203
51% 51%
15%
Net Profit -217 -217
1,014% 1,014%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Livanova PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Livanova PLC Stock News

Neutral
Business Wire
4 days ago
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco. Vladimir Makatsaria, Chief Executive Officer of LivaNova, and Alex Shvartsburg, Chief Financial Officer, will participate in a fireside chat on Wed., Jan. 14, 2026, at 1:30 p.m. Pa...
Neutral
Business Wire
24 days ago
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Th...
Neutral
Business Wire
25 days ago
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. “Lucile is an accomplished health...
More Livanova PLC News

Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular and Neuromodulation. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Vladimir Makatsaria
Employees 2,900
Founded 1987
Website www.livanova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today